Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FLOR (FC303) PET/CT in Metastatic Prostate Cancer
NCT04528199Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of florbetaben in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Adverse Events at 10 days. Started Feb 2021; status: terminated.
02
Drugs
florbetaben
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04528199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528199.